This ACE Clinical Guidance (ACG) highlights the importance of personalised management for patients with early-stage chronic kidney disease (CKD) to delay progression and reduce cardiovascular complications. The ACG offers evidence-based recommendations on optimising blood pressure and albuminuria, with considerations for management in the context of associated comorbid conditions. Principles of tailored lifestyle intervention, regular follow-up, and options for shared or multidisciplinary care are also discussed.
Download the PDF below to access the ACG.
Registered doctors and pharmacists may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A for reading each ACG.
| ACG Recommendations |
| 1. |
Personalise the management plan based on CKD stage, including underlying cause. |
| 2. |
Optimise blood pressure control and albuminuria management with an ACE inhibitor or ARB, and titrate to maximum tolerated dose as needed. |
| 3. |
Add an SGLT2 inhibitor to ACE inhibitor/ARB therapy for patients with CKD and persistent albuminuria, regardless of DM status. |
| 4. |
Optimise management of CKD-related comorbidities. |
| 5. |
Encourage and provide education on lifestyle intervention through shared decision-making. |
| 6. |
Regularly follow up all patients with CKD, with more frequent review for those at increased risk of disease progression. |
| 7. |
Consider shared or multidisciplinary care depending on CKD progression and other clinical needs.
|
CKD – delaying progression and reducing cardiovascular complications (Oct 2023)
CKD – delaying progression and reducing cardiovascular complications references (Oct 2023)
Feedback
Click here to give us feedback on this ACG.
Related ACGs